DCTH vs. GLUE

Last updated Apr 1, 2026

Compare and contrast key facts about Delcath Systems, Inc. (DCTH) and Monte Rosa Therapeutics, Inc. (GLUE).

Performance

DCTH vs. GLUE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Delcath Systems, Inc. (DCTH) and Monte Rosa Therapeutics, Inc. (GLUE). The values are adjusted to include any dividend payments, if applicable.

DCTH vs. GLUE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DCTH Delcath Systems, Inc.	-8.12%	-16.11%	189.42%	15.56%	-53.55%	-29.80%
GLUE Monte Rosa Therapeutics, Inc.	4.91%	125.94%	22.83%	-25.76%	-62.73%	-3.59%

Fundamentals

EPS DCTH : $0.07 GLUE : -$0.72
PS Ratio DCTH : 5.60 GLUE : 7.30
Total Revenue (TTM) DCTH : $64.50M GLUE : $123.67M
Gross Profit (TTM) DCTH : $73.43M GLUE : $118.80M
EBITDA (TTM) DCTH : $1.61M GLUE : -$45.22M

Returns By Period

In the year-to-date period, DCTH achieves a -8.12% return, which is significantly lower than GLUE's 4.91% return.

DCTH

• 1D: 4.39%
• 1M: 4.27%
• YTD: -8.12%
• 6M: -13.67%
• 1Y: -27.10%
• 3Y*: 17.30%
• 5Y*: -5.40%
• 10Y*: —

GLUE

• 1D: 5.92%
• 1M: -7.32%
• YTD: 4.91%
• 6M: 122.00%
• 1Y: 254.53%
• 3Y*: 28.29%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DCTH vs. GLUE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DCTH

DCTH Risk / Return Rank: 24
DCTH Sharpe Ratio Rank: 21
DCTH Sortino Ratio Rank: 21
DCTH Omega Ratio Rank: 23
DCTH Calmar Ratio Rank: 24
DCTH Martin Ratio Rank: 29

GLUE

GLUE Risk / Return Rank: 94
GLUE Sharpe Ratio Rank: 95
GLUE Sortino Ratio Rank: 96
GLUE Omega Ratio Rank: 92
GLUE Calmar Ratio Rank: 94
GLUE Martin Ratio Rank: 93

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DCTH vs. GLUE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Delcath Systems, Inc. (DCTH) and Monte Rosa Therapeutics, Inc. (GLUE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DCTH	GLUE	Difference
Sharpe ratio Return per unit of total volatility	-0.47	2.68	-3.14
Sortino ratio Return per unit of downside risk	-0.39	3.77	-4.16
Omega ratio Gain probability vs. loss probability	0.95	1.43	-0.48
Calmar ratio Return relative to maximum drawdown	-0.54	5.32	-5.86
Martin ratio Return relative to average drawdown	-0.77	12.85	-13.62
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DCTH vs. GLUE - Sharpe Ratio Comparison

The current DCTH Sharpe Ratio is -0.47, which is lower than the GLUE Sharpe Ratio of 2.68. The chart below compares the historical Sharpe Ratios of DCTH and GLUE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DCTH	GLUE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.47	2.68	-3.14
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.07	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.45	-0.05	-0.40

Correlation

The correlation between DCTH and GLUE is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

DCTH vs. GLUE - Dividend Comparison

Neither DCTH nor GLUE has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

DCTH vs. GLUE - Drawdown Comparison

The maximum DCTH drawdown since its inception was -99.96%, which is greater than GLUE's maximum drawdown of -94.08%. Use the drawdown chart below to compare losses from any high point for DCTH and GLUE.

Drawdown Indicators

	DCTH	GLUE	Difference
Max Drawdown Largest peak-to-trough decline	-99.96%	-94.08%	-5.88%
Max Drawdown (1Y) Largest decline over 1 year	-54.75%	-41.84%	-12.91%
Max Drawdown (5Y) Largest decline over 5 years	-85.10%	—	—
Current Drawdown Current decline from peak	-99.85%	-61.03%	-38.82%
Average Drawdown Average peak-to-trough decline	-96.38%	-75.32%	-21.06%
Ulcer Index Depth and duration of drawdowns from previous peaks	38.26%	17.32%	+20.94%

Volatility

DCTH vs. GLUE - Volatility Comparison

The current volatility for Delcath Systems, Inc. (DCTH) is 12.83%, while Monte Rosa Therapeutics, Inc. (GLUE) has a volatility of 14.31%. This indicates that DCTH experiences smaller price fluctuations and is considered to be less risky than GLUE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DCTH	GLUE	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.83%	14.31%	-1.48%
Volatility (6M) Calculated over the trailing 6-month period	36.46%	63.89%	-27.43%
Volatility (1Y) Calculated over the trailing 1-year period	58.48%	96.16%	-37.68%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	74.15%	102.69%	-28.54%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	111.20%	102.69%	+8.51%

Financials